Apellis Pharmaceuticals Stock Filter Stocks by Fundamentals
| APLS Stock | USD 28.00 0.08 0.29% |
Apellis Pharmaceuticals fundamentals help investors to digest information that contributes to Apellis Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Apellis Stock. The fundamental analysis module provides a way to measure Apellis Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Apellis Pharmaceuticals stock.
Apellis | Shares Owned by Institutions |
Apellis Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Apellis Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Apellis Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Apellis Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Apellis Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Apellis Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Apellis Pharmaceuticals' value.| Shares | Deep Track Capital, Lp | 2024-06-30 | 2.5 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.1 M | Deutsche Bank Ag | 2024-06-30 | 1.8 M | Geode Capital Management, Llc | 2024-06-30 | 1.8 M | Boxer Capital Llc | 2024-06-30 | 1.7 M | Artal Group S A | 2024-06-30 | 1.5 M | Fiera Capital Corporation | 2024-06-30 | 1.4 M | Orbimed Advisors, Llc | 2024-06-30 | 1.3 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 1.3 M | Wellington Management Company Llp | 2024-06-30 | 16.4 M | Ecor1 Capital, Llc | 2024-06-30 | 11.6 M |
Apellis Fundamentals
| Return On Equity | -1.09 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (0.53) % | ||||
| Operating Margin | (0.15) % | ||||
| Current Valuation | 3.52 B | ||||
| Shares Outstanding | 121.77 M | ||||
| Shares Owned By Insiders | 14.28 % | ||||
| Shares Owned By Institutions | 96.89 % | ||||
| Number Of Shares Shorted | 15.26 M | ||||
| Price To Earning | (6.94) X | ||||
| Price To Book | 12.90 X | ||||
| Price To Sales | 5.42 X | ||||
| Revenue | 396.59 M | ||||
| Gross Profit | 69.79 M | ||||
| EBITDA | (515.42 M) | ||||
| Net Income | (528.63 M) | ||||
| Cash And Equivalents | 852.8 M | ||||
| Cash Per Share | 7.76 X | ||||
| Total Debt | 110.93 M | ||||
| Debt To Equity | 0.63 % | ||||
| Current Ratio | 7.57 X | ||||
| Book Value Per Share | 2.17 X | ||||
| Cash Flow From Operations | (594.74 M) | ||||
| Short Ratio | 8.21 X | ||||
| Earnings Per Share | (2.72) X | ||||
| Price To Earnings To Growth | (0.30) X | ||||
| Target Price | 68.56 | ||||
| Number Of Employees | 702 | ||||
| Beta | 0.87 | ||||
| Market Capitalization | 3.41 B | ||||
| Total Asset | 788.73 M | ||||
| Retained Earnings | (2.84 B) | ||||
| Working Capital | 518.74 M | ||||
| Current Asset | 115.82 M | ||||
| Current Liabilities | 5.13 M | ||||
| Net Asset | 788.73 M |
About Apellis Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Apellis Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apellis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apellis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.